Both in Biotechnology
SAB Biotherapeutics vs Lineage Cell Therapeutics
Over the past year SABS returned +6.0% and LCTX returned −39.9%; their daily moves had a correlation of 0.20.
SABS +6.0% LCTX −39.9%Growth of $1, one year, split-adjusted
| Metric | SABS | LCTX |
|---|---|---|
| Price | $3.16 | $1.03 |
| Market cap | $287.1M | $259.2M |
| Today | +2.77% | −0.49% |
| 1 month | −2.0% | +8.2% |
| 6 months | −9.3% | −29.8% |
| Year to date | −15.6% | −38.6% |
| 1 year | +4.1% | −41.4% |
| Revenue growth (YoY) | — | −61.3% |
| Gross margin | — | 100.0% |
| Net margin | — | 138.6% |
| P/E (TTM) | — | — |
| Price / sales | — | 19.8× |
| Net cash | $99.4M | $50.8M |
| Dividend yield | — | — |
| Volatility (60d) | 55.0% | 52.7% |
| Short % of float | 6.2% | 12.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).